Fakih, M., Chen, E. X., Lee, K., Bekaii-Saab, T. S., Lonardi, S., Gong, J., Elez, E., Lau, J., Breton, V., Khan, O., Chertkova, O., Jain, S., Han, S. (2026). Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for
                    <i>PIK3CA</i>
                    -mutated (mut) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.158